drugset / Trial / NCT02639650
Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor
Phase 3
Unknown
214 enrolled
Weiguo Lv
First Affiliated Hospital of Zhongshan Medical University · collabHuazhong University of Science and Technology · collabShandong University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial is designed to study the effect and safety of paclitaxel plus cisplatin as the first-line regimen in the treatment of high risk gestational trophoblastic tumor.
Timeline
- Start
- 2016-03-01
- Primary completion
- 2024-03-01
- Completion
- 2026-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | 50 mg/m2 | — |
| Comparator | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Comparator | Dactinomycin | Protein / enzyme biologic | 500 ug | Intravenous |
| Comparator | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Comparator | Methotrexate | Small molecule | 100 mg/m2 | Intravenous |
| Comparator | Methotrexate | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | — |
| Comparator | Vincristine | Small molecule | 1 mg/m2 | — |